WldS mice are protected against the Parkinsonian mimetic MPTP
WldS mice are protected against the Parkinsonian mimetic MPTP
复制标题
DOI：
10.1016/j.expneurol.2006.05.017
复制
发表时间：
2006-11-01
影响因子：
5.3
通讯作者：
O'Malley, Karen L.
中科院分区：
文献类型：
--
作者：
Hasbani, Daphne M.;O'Malley, Karen L.
黑质纹状体通路的逐渐丧失是帕金森病的一个显著特征。由于终端野丢失似乎先于细胞体丢失，我们测试了小鼠突变体Wld(S)是否会改善帕金森模拟1-甲基-4-苯基-1,2,3,6-四氢吡啶（MPTP）治疗后的黑质纹状体变性。Wld(S)在多种疾病中延迟轴突变性。目前的研究结果表明，Wld(S)基因产物可以提高存活率，防止黑质纹状体轴突变性，减轻神经递质损失，但不能拯救细胞体。由于MPTP被认为损害线粒体能量的产生，这些数据表明Wld(S)基因产物可以改善代谢功能障碍引起的疾病病理。这些结果为帕金森病提供了新的治疗途径。(c) 2006爱思唯尔公司版权所有。
The progressive loss of the nigrostriatal pathway is a distinguishing feature of Parkinson's disease. Because terminal field loss appears to precede cell body loss, we tested whether the mouse mutant Wld(S), which delays axonal degeneration in a variety of disorders, would ameliorate nigrostriatal degeneration following treatment with the Parkinsonian mimetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The present findings show that the Wld(S) gene product enhances survival, prevents nigrostriatal axon degeneration, and attenuates neurotransmitter loss but does not rescue cell bodies. As MPTP is thought to impair mitochondrial energy production, these data suggest that disease pathology due to metabolic dysfunction could be improved by the Wld(S) gene product. These results suggest new therapeutic avenues for Parkinson's disease. (c) 2006 Elsevier Inc. All rights reserved.